- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05458011
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients
Primary Objective:
To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.
Secondary Objectives:
- To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.
- To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Teva U.S. Medical Information
- Phone Number: 1-888-483-8279
- Email: USMedInfo@tevapharm.com
Study Locations
-
-
-
Baotou Shi, China, 014060
- Teva Investigational Site 88028
-
Beijing, China, 100853
- Teva Investigational Site 88001
-
Beijing Shi, China, 100044
- Teva Investigational Site 88004
-
Changchun, China, 130021
- Teva Investigational Site 88008
-
Changchun, China, 130041
- Teva Investigational Site 88009
-
Changsha Shi, China, 410008
- Teva Investigational Site 88022
-
Changsha Shi, China, 410013
- Teva Investigational Site 88030
-
Chengdu Shi, China, 610041
- Teva Investigational Site 88003
-
Chongqing, China, 400700
- Teva Investigational Site 88029
-
Fuzhou, China, 350001
- Teva Investigational Site 88019
-
Guangzhou Shi, China, 510260
- Teva Investigational Site 88020
-
Guiyang, China, 550004
- Teva Investigational Site 88013
-
Harbin Shi, China, 150001
- Teva Investigational Site 88026
-
Lianyungang, China, 222002
- Teva Investigational Site 88010
-
Luoyang, China, 4710039
- Teva Investigational Site 88005
-
Rizhao, China, 276800
- Teva Investigational Site 88033
-
Shanghaishi, China, 200040
- Teva Investigational Site 88021
-
Shanghaishi, China, 200120
- Teva Investigational Site 88025
-
Shenyang Shi, China, 110016
- Teva Investigational Site 88016
-
Shijiazhuang Shi, China, 50073
- Teva Investigational Site 88011
-
Suzhou Shi, China, 215004
- Teva Investigational Site 88015
-
Tianjin Shi, China, 300052
- Teva Investigational Site 88024
-
Tianjin Shi, China, 300120
- Teva Investigational Site 88023
-
Wenzhou, China, 325000
- Teva Investigational Site 88017
-
Wuhan Shi, China, 430030
- Teva Investigational Site 88012
-
Wuhan Shi, China, 430071
- Teva Investigational Site 88006
-
Xining Shi, China, 810007
- Teva Investigational Site 88032
-
Zhanjiang, China, 524008
- Teva Investigational Site 88031
-
Zhengzhou Shi, China, 450003
- Teva Investigational Site 88034
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant has a diagnosis of migraine with onset at ≤50 years of age.
- The participant has a body weight ≥45 kg and body mass index within the range 17.5 to 34.9 kg/m2 (inclusive).
- The participant has a history of migraine for ≥12 months prior to screening.
- Women of childbearing potential (WOCBP) whose male partners are potentially fertile (that is; no vasectomy) must use highly effective birth control methods for the duration of the study and for 6.0 months after discontinuation of investigational medicinal product (IMP).
- Men must be sterile or, if they are potentially fertile/reproductively competent (not congenitally sterile) and their female partners are of childbearing potential, should use highly effective birth control for the duration of the study.
- Additional criteria apply, please contact the investigator for more information.
Exclusion Criteria:
- Use of medications containing opioids (including codeine), barbiturates (including butalbital), or any combination product containing opioids or barbiturates (including butalbital) on more than 4 days during the screening period for the treatment of migraine or for any other reason.
- Has used an intervention/device (eg, scheduled nerve blocks or transcranial magnetic stimulation) for migraine, or in the head or neck area, during the 2 months prior to screening (visit 1).
- History of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological [eg, cerebral ischemia], or peripheral extremity ischemia or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism.
- History of human immunodeficiency virus, tuberculosis, Lyme disease, or a known or suspected active infection of coronavirus disease 2019 (COVID-19).
- Known current infection or history of infection in the past 6 months with hepatitis B or C viruses.
- History of cancer in the past 5 years, except for appropriately treated non-melanoma skin carcinoma.
- History of hypersensitivity reactions to injected proteins, including monoclonal antibodies (mAbs), or a history of Stevens-Johnson Syndrome or toxic epidermal necrolysis syndrome, or is concomitantly using lamotrigine.
- Any clinically significant uncontrolled medical condition (treated or untreated).
- History of alcohol or drug abuse during the past 2 years or drug dependence during the past 5 years.
- Additional criteria apply, please contact the investigator for more information.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fremanezumab Monthly
Double Blind (DB) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks). Participants will receive a single injection of fremanezumab and two placebo injections on Day 1, and a single injection of fremanezumab on Days 29 and 57. Open Label (OL) Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141. |
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection
Other Names:
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection |
Experimental: Fremanezumab Quarterly
DB Period: Participants will receive fremanezumab once a quarter (once at the beginning of the 12-week double-blind treatment period). Participants will receive 3 injections of fremanezumab on Day 1, and a single placebo injection on Days 29 and 57. OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141. |
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection
Other Names:
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection |
Placebo Comparator: Placebo
DB Period: Participants will receive placebo once a month (approximately every 4 weeks). Participants will receive 3 placebo injections on Day 1, and a single injection of placebo on Days 29 and 57. OL Period: Participants will receive fremanezumab once a month (approximately every 4 weeks) administered as a single injection on Days 85, 113, and 141. |
Pharmaceutical form: solution for injection Route of administration: subcutaneous injection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Double Blind (DB) Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab
Time Frame: Baseline Period (Day -28 to Day -1), Week 12
|
Baseline Period (Day -28 to Day -1), Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DB Period: Change From Baseline in the Average Number of Migraine Days During the 4-Week Period After the First Dose of Fremanezumab
Time Frame: Baseline Period (Day -28 to Day -1), Up to Week 4
|
Baseline Period (Day -28 to Day -1), Up to Week 4
|
DB Period: Change From Baseline in the Monthly Average Number of Days of Use of Any Acute Headache Medications During the 12-Week Period After the First Dose of Fremanezumab
Time Frame: Baseline Period (Day -28 to Day -1), Up to Week 12
|
Baseline Period (Day -28 to Day -1), Up to Week 12
|
DB Period: Percentage of Participants Reaching at Least 50 Percent (%) Reduction From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab
Time Frame: Baseline Period (Day -28 to Day-1), Up to Week 12
|
Baseline Period (Day -28 to Day-1), Up to Week 12
|
DB Period: Change From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Period After the First Dose of Fremanezumab
Time Frame: Baseline Period (Day -28 to Day -1), Up to Week 12
|
Baseline Period (Day -28 to Day -1), Up to Week 12
|
Number of Participants Who Experience Adverse Events (AEs)
Time Frame: Baseline Visit (Day 1), Up to Week 32
|
Baseline Visit (Day 1), Up to Week 32
|
Number of Participants Who Do Not Complete the Study Due to Adverse Events
Time Frame: Up to Week 32
|
Up to Week 32
|
Number of Participants Who Receive Concomitant Medications
Time Frame: Baseline Visit (Day 1), Up to Week 32
|
Baseline Visit (Day 1), Up to Week 32
|
Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADA)
Time Frame: Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Assessment of Anti-Drug Antibodies in Plasma Level by Titer
Time Frame: Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Assessment of Anti-Drug Antibodies in Plasma Level by Kinetics
Time Frame: Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Assessment of Anti-Drug Antibodies in Plasma Level by Neutralizing Activities
Time Frame: Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Baseline Visit (Day 1), Day 57, Day 169, Day 225
|
Collaborators and Investigators
Investigators
- Study Director: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TV48125-CNS-30088
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Fremanezumab
-
Teva Branded Pharmaceutical Products R&D, Inc.No longer availableMigraineBelgium, Canada, Czechia, Italy, Spain, Sweden, United Kingdom
-
Hospital Clínico Universitario de ValladolidUniversity of Valladolid; Complejo Asistencial Universitario de Palencia; Complejo...RecruitingBrain Diseases | Migraine Disorders | Migraine Without Aura | Migraine With AuraSpain
-
Mayo ClinicWithdrawnMigraine | Cadasil
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedCluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingMigraineUnited States, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Canada
-
Teva Branded Pharmaceutical Products R&D, Inc.Withdrawn
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedChronic Cluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMigraineUnited States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingMigraineUnited States, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Canada
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMigraineUnited States, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain